Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy and TPP Insights

Thelansis’s “Metastatic Castration-Resistant Prostate Cancer (mCRPC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Metastatic Castration-Resistant Prostate Cancer (mCRPC) Overview

Metastatic castration-resistant prostate cancer (mCRPC) is an advanced, lethal malignancy defined by disease progression despite castrate levels of serum testosterone, driven by androgen receptor amplification, splice variants, or autonomous intra-tumoral steroidogenesis. It characteristically metastasizes to bone, regional lymph nodes, and visceral organs, presenting with bone pain, pathological fractures, spinal cord compression, and constitutional cachexia. Diagnosis integrates serial prostate-specific antigen tracking, bone scintigraphy, and advanced prostate-specific membrane antigen (PSMA) PET imaging, alongside mandatory genomic sequencing to identify actionable mutations. The 2026 therapeutic paradigm prioritizes biomarker-driven personalization over rigid sequencing, utilizing androgen receptor pathway inhibitors like abiraterone or enzalutamide, or taxane chemotherapies like docetaxel and cabazitaxel. For patients harboring homologous recombination repair alterations, particularly BRCA1 or BRCA2 mutations, frontline combination therapy pairing PARP inhibitors like talazoparib with enzalutamide has demonstrated definitive survival advantages. Furthermore, radioligand therapy with lutetium Lu 177 vipivotide tetraxetan is a standard of care for PSMA-positive disease following pathway inhibitor progression, while bone-targeted agents like denosumab are routinely added to lifelong androgen deprivation therapy to manage skeletal events and optimize survival.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)